Compare KBDC & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KBDC | ARDX |
|---|---|---|
| Founded | 2021 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 822.8M | 797.8M |
| IPO Year | 2018 | 2014 |
| Metric | KBDC | ARDX |
|---|---|---|
| Price | $13.00 | $3.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $14.50 | $12.80 |
| AVG Volume (30 Days) | 398.5K | ★ 4.7M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | ★ 12.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.85 | N/A |
| Revenue | N/A | ★ $2,607,000.00 |
| Revenue This Year | N/A | $18.42 |
| Revenue Next Year | N/A | $28.82 |
| P/E Ratio | $15.29 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.14 | $2.96 |
| 52 Week High | $15.87 | $8.40 |
| Indicator | KBDC | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 53.25 | 38.51 |
| Support Level | $12.88 | N/A |
| Resistance Level | $13.65 | $3.35 |
| Average True Range (ATR) | 0.28 | 0.13 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 76.00 | 21.37 |
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company, investing mainly in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation mainly through debt investments in middle-market companies.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.